DGAP-News: Elanix Biotechnologies AG: Announces Subscription Price for New Shares in Capital Increase
10.11.2017 (www.4investors.de) -
DGAP-News: Elanix Biotechnologies AG / Key word(s): Capital Increase/Financing
Elanix Biotechnologies AG: Announces Subscription Price for New Shares in Capital Increase
10.11.2017 / 16:32
The issuer is solely responsible for the content of this announcement.
The information in this announcement is NOT for publication OR distribution in or into the United States of America, Australia, Canada or any jurisdiction in which such distribution or publication could be unlawful
Elanix Biotechnologies AG Announces Subscription Price for New Shares in Capital Increase
Berlin, November 10, 2017 -Elanix Biotechnologies AG ("Company"), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, today set the subscription price for the cash capital increase at EUR 3.75 per new share.
As announced in the Ad-hoc announcement of the same day, the company's shareholders, at the Annual General Meeting of 24 August 2017, resolved a cash capital increase by way of a rights offering to existing shareholders (indirect subscription rights). A total of up to 1,699,800 new shares will be offered for subscription to the shareholders at a ratio of 4:1 (four existing shares allow a subscription of 1 new share). Any new shares not subscribed will be offered to existing shareholders as supplemental subscriptions as well as to selected investors through a Private Placement. Expected proceeds from the offering will be used to fund corporate growth and further development of progenitor cell products.
The subscription period is expected to start on 23 November 2017, subject to approval of the prospectus by BaFin. The shares of Elanix Biotechnologies AG are expected to be traded with the attached subscription rights until 20 November 2017. Accordingly, shareholders who hold shares on that date will receive subscription rights. The subscription offer, as well as the prospectus once approved, will be published on the website of Elanix Biotechnologies AG at www.elanixbiotechnologies.com.
Elanix Biotechnologies AG develops and commercializes tissue regeneration products for wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix Biotechnologies owns GMP certified Master and Working human cell banks with vast quantities of cells.
Elanix Biotechnologies AG has its registered office in Berlin, Germany, with an office in Wiesbaden, Germany, and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market (General Standard) on the Frankfurt Stock Exchange under the ISIN DE000A0WMJQ4 (symbol ELN). Further information can be found at www.elanixbiotechnologies.com.
Tomas Svoboda, CEO
Tel: +41 22 363 66 40
Tel: +44 (0)20 7318 2955
This publication contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties, such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Elanix Biotechnologies AG disclaims any obligation to update these forward-looking statements.
This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of Elanix Biotechnologies AG in the United States of America, Germany or any other jurisdiction. Nor does this disclosure constitute a prospectus within the meaning of EU Directive 2003/71/EC of the European Parliament and of the Council of November 4, 2003, as amended (the "Prospectus Directive"). Any public offering in Germany may only be made on the basis of a prospectus. Once approved by the Federal Financial Supervisory Authority (BaFin), the prospectus will be published on Elanix Biotechnologies AG's website. Any decision to invest in subscription rights or shares of Elanix Biotechnologies AG should be made solely on the basis of the prospectus.
Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein may not be offered or sold in the United States of America in the absence of registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of Elanix Biotechnologies AG have not been, and will not be, registered under the Securities Act.
This announcement does not constitute a recommendation concerning the placement of securities described in this announcement. Investors should consult a professional advisor as to the suitability of the Placement for the person concerned.
In the United Kingdom, this document is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended)(the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
In member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer, if made subsequently, is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive. For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.
No action has been taken that would permit an offering of the securities, a purchase of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.
10.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Elanix Biotechnologies AG
Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf
End of News
DGAP News Service
Francotyp-Postalia hat das Tor zum Internet der Dinge
IPO-Kandidat Homes + Holiday: „Unser Geschäftsmodell hat sich bewährt und ist skalierbar“
Staramba: „Wir haben unsere Lehren gezogen“